Adipokines as uremic toxins
- PMID: 22200420
- DOI: 10.1053/j.jrn.2011.10.029
Adipokines as uremic toxins
Abstract
The adipose tissue has pleiotropic functions far beyond the mere storage of energy, and it secretes a number of hormones and cytokines, called adipokines, which have biological effects that impact heath and disease. Adipokines are markedly elevated in the plasma of uremic patients, mainly due to decreased renal excretion. They have pluripotent signaling effects on inflammation/oxidative stress (leptin, adiponectin, resistin), protein-energy wasting (leptin, adiponectin), insulin signaling (adiponectin, leptin, visfatin), endothelial dysfunction (visfatin), and vascular damage (adiponectin, leptin, resistin), which are prevalent in uremic patients. Obesity superimposed to uremia may further aggravate hyperadipokinemia, with the exception of adiponectinemia, which is mitigated by adiposity. Among adipokines and until more data become available, only leptin may be considered as a full uremic toxin owing to adverse effects on protein-energy wasting, cardiovascular damage, inflammation, and the immune system, which have been documented both clinically and experimentally. Resistin and visfatin display some features of uremic toxins, but more data are needed to consider these adipokines as true uremic toxins. In contrast, high levels of adiponectin and chemerin seen in uremia appear to be beneficial. Further research is needed to investigate whether selective removal of leptin, resistin, and visfatin and increments of adiponectin and chemerin levels may have clinical relevance in uremic patients.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Adipokines: the missing link between insulin resistance and obesity.Diabetes Metab. 2008 Feb;34(1):2-11. doi: 10.1016/j.diabet.2007.09.004. Diabetes Metab. 2008. PMID: 18093861 Review.
-
Adipokines as emerging mediators of immune response and inflammation.Nat Clin Pract Rheumatol. 2007 Dec;3(12):716-24. doi: 10.1038/ncprheum0674. Nat Clin Pract Rheumatol. 2007. PMID: 18037931 Review.
-
Role of fat mass and adipokines in chronic kidney disease.Curr Opin Nephrol Hypertens. 2008 Jan;17(1):25-31. doi: 10.1097/MNH.0b013e3282f2905f. Curr Opin Nephrol Hypertens. 2008. PMID: 18090666 Review.
-
Obesity in chronic kidney disease: good or bad?Blood Purif. 2008;26(1):23-9. doi: 10.1159/000110559. Epub 2008 Jan 10. Blood Purif. 2008. PMID: 18182791 Review.
-
Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.Clin Sci (Lond). 2008 Feb;114(4):275-88. doi: 10.1042/CS20070196. Clin Sci (Lond). 2008. PMID: 18194136 Review.
Cited by
-
Immune dysfunction in uremia—an update.Toxins (Basel). 2012 Oct 24;4(11):962-90. doi: 10.3390/toxins4110962. Toxins (Basel). 2012. PMID: 23202302 Free PMC article. Review.
-
Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease.Nutr Metab Cardiovasc Dis. 2020 Jul 24;30(8):1375-1381. doi: 10.1016/j.numecd.2020.04.012. Epub 2020 Apr 21. Nutr Metab Cardiovasc Dis. 2020. PMID: 32571614 Free PMC article. Clinical Trial.
-
Immune Dysfunction in Uremia 2020.Toxins (Basel). 2020 Jul 5;12(7):439. doi: 10.3390/toxins12070439. Toxins (Basel). 2020. PMID: 32635646 Free PMC article. Review.
-
Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.PLoS One. 2014 Oct 16;9(10):e109134. doi: 10.1371/journal.pone.0109134. eCollection 2014. PLoS One. 2014. PMID: 25330088 Free PMC article. Clinical Trial.
-
Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients.Biomed Res Int. 2017;2017:3713025. doi: 10.1155/2017/3713025. Epub 2017 Oct 31. Biomed Res Int. 2017. PMID: 29226133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources